| Temsirolimus | hsa00052 | Galactose metabolism | 1.12E-04 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Temsirolimus | hsa00280 | Valine, leucine and isoleucine degradation | 3.41E-03 | 4 | P55809, Q9HCC0, Q02252, P11310 | OXCT1, MCCC2, ALDH6A1, ACADM | More | |
| Temsirolimus | hsa00500 | Starch and sucrose metabolism | 3.16E-04 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Temsirolimus | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Temsirolimus | hsa00730 | Thiamine metabolism | 2.53E-05 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Temsirolimus | hsa00770 | Pantothenate and CoA biosynthesis | 5.59E-03 | 2 | O95498, O95497 | VNN2, VNN1 | More | |
| Temsirolimus | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.20E-02 | 2 | P78417, P11766 | GSTO1, ADH5 | More | |
| Temsirolimus | hsa00982 | Drug metabolism - cytochrome P450 | 3.20E-02 | 2 | P78417, P11766 | GSTO1, ADH5 | More | |
| Temsirolimus | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Temsirolimus | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.60E-02 | 2 | P17252, Q9NRA1 | PRKCA, PDGFC | More | |
| Temsirolimus | hsa03013 | RNA transport | 4.13E-02 | 6 | Q09161, P35658, P47813, Q14152, O75822, P51114 | NCBP1, NUP214, EIF1AX, EIF3A, EIF3J, FXR1 | More | |
| Temsirolimus | hsa03060 | Protein export | 4.22E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
| Temsirolimus | hsa04014 | Ras signaling pathway | 5.92E-04 | 5 | Q9NRA1, P49767, P17252, Q14644, P62873 | PDGFC, VEGFC, PRKCA, RASA3, GNB1 | More | |
| Temsirolimus | hsa04015 | Rap1 signaling pathway | 4.88E-04 | 5 | Q9NRA1, P49767, P25116, P08514, P17252 | PDGFC, VEGFC, F2R, ITGA2B, PRKCA | More | |
| Temsirolimus | hsa04020 | Calcium signaling pathway | 2.39E-03 | 4 | P17252, P25116, Q9NRA1, P49767 | PRKCA, F2R, PDGFC, VEGFC | More | |
| Temsirolimus | hsa04060 | Cytokine-cytokine receptor interaction | 3.62E-02 | 4 | P27930, P14778, P25024, P25025 | IL1R2, IL1R1, CXCR1, CXCR2 | More | |
| Temsirolimus | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.60E-02 | 3 | Q8NHW4, P61073, Q13651 | CCL4L2, CXCR4, IL10RA | More | |
| Temsirolimus | hsa04064 | NF-kappa B signaling pathway | 4.09E-03 | 5 | P01584, P67870, P63279, Q8NHW4, Q9NQC7 | IL1B, CSNK2B, UBE2I, CCL4L2, CYLD | More | |
| Temsirolimus | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
| Temsirolimus | hsa04072 | Phospholipase D signaling pathway | 6.69E-05 | 7 | Q9UQC2, P25116, P25024, P25025, P17252, P23743, Q9NRA1 | GAB2, F2R, CXCR1, CXCR2, PRKCA, DGKA, PDGFC | More | |
| Temsirolimus | hsa04151 | PI3K-Akt signaling pathway | 1.71E-03 | 6 | P25116, Q9NRA1, P49767, P62873, P08514, P17252 | F2R, PDGFC, VEGFC, GNB1, ITGA2B, PRKCA | More | |
| Temsirolimus | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Temsirolimus | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Temsirolimus | hsa04260 | Cardiac muscle contraction | 4.49E-02 | 3 | P67936, P13073, P12074 | TPM4, COX4I1, COX6A1 | More | |
| Temsirolimus | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Temsirolimus | hsa04371 | Apelin signaling pathway | 4.39E-02 | 4 | P63218, P50151, Q14344, Q13485 | GNG5, GNG10, GNA13, SMAD4 | More | |
| Temsirolimus | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Temsirolimus | hsa04510 | Focal adhesion | 8.11E-03 | 4 | P08514, P17252, Q9NRA1, P49767 | ITGA2B, PRKCA, PDGFC, VEGFC | More | |
| Temsirolimus | hsa04512 | ECM-receptor interaction | 3.19E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | |
| Temsirolimus | hsa04540 | Gap junction | 2.29E-03 | 3 | P17252, P68371, Q9NRA1 | PRKCA, TUBB2C, PDGFC | More | |
| Temsirolimus | hsa04611 | Platelet activation | 7.90E-03 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | |
| Temsirolimus | hsa04613 | Neutrophil extracellular trap formation | 2.31E-02 | 4 | P17252, O60814, P08514, P07359 | PRKCA, H2BC12, ITGA2B, GP1BA | More | |
| Temsirolimus | hsa04623 | Cytosolic DNA-sensing pathway | 1.54E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | |
| Temsirolimus | hsa04640 | Hematopoietic cell lineage | 2.96E-02 | 3 | P07359, P08514, P04141 | GP1BA, ITGA2B, CSF2 | More | |
| Temsirolimus | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | |
| Temsirolimus | hsa04659 | Th17 cell differentiation | 3.17E-02 | 3 | P25963, P84022, Q13485 | NFKBIA, SMAD3, SMAD4 | More | |
| Temsirolimus | hsa04664 | Fc epsilon RI signaling pathway | 2.60E-02 | 2 | P04141, P17252 | CSF2, PRKCA | More | |
| Temsirolimus | hsa04713 | Circadian entrainment | 4.51E-02 | 2 | P17252, P62873 | PRKCA, GNB1 | More | |
| Temsirolimus | hsa04723 | Retrograde endocannabinoid signaling | 3.83E-02 | 2 | P17252, P62873 | PRKCA, GNB1 | More | |
| Temsirolimus | hsa04724 | Glutamatergic synapse | 3.09E-03 | 3 | P17252, P62873, Q9NSB8 | PRKCA, GNB1, HOMER2 | More | |
| Temsirolimus | hsa04725 | Cholinergic synapse | 3.83E-02 | 2 | P17252, P62873 | PRKCA, GNB1 | More | |
| Temsirolimus | hsa04726 | Serotonergic synapse | 6.44E-03 | 3 | P17252, P62873, P18054 | PRKCA, GNB1, ALOX12 | More | |
| Temsirolimus | hsa04727 | GABAergic synapse | 2.06E-02 | 2 | P62873, P17252 | GNB1, PRKCA | More | |
| Temsirolimus | hsa04730 | Long-term depression | 3.20E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | |
| Temsirolimus | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.51E-02 | 2 | P18054, P17252 | ALOX12, PRKCA | More | |
| Temsirolimus | hsa04810 | Regulation of actin cytoskeleton | 2.06E-02 | 3 | P08514, Q9NRA1, P25116 | ITGA2B, PDGFC, F2R | More | |
| Temsirolimus | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Temsirolimus | hsa04918 | Thyroid hormone synthesis | 1.14E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
| Temsirolimus | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Temsirolimus | hsa04926 | Relaxin signaling pathway | 1.14E-02 | 3 | P62873, P49767, P17252 | GNB1, VEGFC, PRKCA | More | |
| Temsirolimus | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Temsirolimus | hsa04932 | Non-alcoholic fatty liver disease | 1.24E-02 | 6 | O43521, O75460, P01584, P13073, P12074, O15239 | BCL2L11, ERN1, IL1B, COX4I1, COX6A1, NDUFA1 | More | |
| Temsirolimus | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Temsirolimus | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | |
| Temsirolimus | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | |
| Temsirolimus | hsa05010 | Alzheimer disease | 2.21E-02 | 10 | O15239, P13073, P12074, Q00535, O75460, P0DP23, P01584, O95197, P67870, P28070 | NDUFA1, COX4I1, COX6A1, CDK5, ERN1, CALM1, IL1B, RTN3, CSNK2B, PSMB4 | More | |
| Temsirolimus | hsa05032 | Morphine addiction | 1.20E-03 | 6 | P62873, P63218, P50151, Q07343, P17252, P43250 | GNB1, GNG5, GNG10, PDE4B, PRKCA, GRK6 | More | |
| Temsirolimus | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.73E-02 | 2 | P25024, P25025 | CXCR1, CXCR2 | More | |
| Temsirolimus | hsa05130 | Pathogenic Escherichia coli infection | 3.65E-02 | 3 | Q14247, P68371, P25116 | CTTN, TUBB2C, F2R | More | |
| Temsirolimus | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | |
| Temsirolimus | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Temsirolimus | hsa05150 | Staphylococcus aureus infection | 2.44E-02 | 4 | P21462, Q14532, P59665, P59666 | FPR1, KRT32, DEFA1; DEFA1B, DEFA3 | More | |
| Temsirolimus | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Temsirolimus | hsa05163 | Human cytomegalovirus infection | 2.89E-02 | 7 | P0DP23, Q8NHW4, Q08828, P23458, P01584, P61073, Q13651 | CALM1, CCL4L2, ADCY1, JAK1, IL1B, CXCR4, IL10RA | More | |
| Temsirolimus | hsa05200 | Pathways in cancer | 1.37E-02 | 6 | P08514, P17252, P49767, P25116, P62873, P78417 | ITGA2B, PRKCA, VEGFC, F2R, GNB1, GSTO1 | More | |
| Temsirolimus | hsa05205 | Proteoglycans in cancer | 4.43E-02 | 3 | Q12955, Q14247, P17252 | ANK3, CTTN, PRKCA | More | |
| Temsirolimus | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Temsirolimus | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | |
| Temsirolimus | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
| Temsirolimus | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Temsirolimus | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Temsirolimus | hsa05231 | Choline metabolism in cancer | 2.29E-03 | 3 | Q9NRA1, P23743, P17252 | PDGFC, DGKA, PRKCA | More | |
